Abbott RealTime Hepatitis C Virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV Assays for Prediction of Sustained Virological Response to Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients
-
Published:2009-02
Issue:2
Volume:47
Page:385-389
-
ISSN:0095-1137
-
Container-title:Journal of Clinical Microbiology
-
language:en
-
Short-container-title:J Clin Microbiol
Author:
Matsuura Kentaro12, Tanaka Yasuhito1, Hasegawa Izumi3, Ohno Tomoyoshi3, Tokuda Hiroshi4, Kurbanov Fuat1, Sugauchi Fuminaka2, Nojiri Shunsuke2, Joh Takashi2, Mizokami Masashi5
Affiliation:
1. Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan 2. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan 3. Department of Gastroenterology, Social Insurance Chukyo Hospital, Nagoya, Japan 4. Department of Internal Medicine, Nagoya City Johoku Hospital, Nagoya, Japan 5. Research Center for Hepatitis and Immunology, Kohnodai Hospital International Medical Center of Japan, Ichikawa, Japan
Abstract
ABSTRACT
Two commercial real-time PCR assays are currently available for sensitive hepatitis C virus (HCV) RNA quantification: the Abbott RealTime HCV assay (ART) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assay (CAP/CTM). We assessed whether the two real-time PCR assays were more effective than Roche Cobas Amplicor HCV Monitor test, v.2.0 (CAM) for prediction of the sustained virological response (SVR) to pegylated interferon (PEG-IFN) plus ribavirin (RBV) in chronic hepatitis C. Sixty patients chronically infected with HCV genotype 1b (37 males and 23 females, 53 ± 12 years of age) were treated with PEG-IFNα2b plus RBV for 48 weeks. Stored specimens at nine time points for each patient (at baseline, on treatment, and 24 weeks after treatment) were tested by the two real-time PCR assays and CAM. Twenty-six (43.3%) patients reached SVR. The positive predictive values (PPVs) for SVR of undetectable HCV RNA at week 12 by CAM, ART, and CAP/CTM were 74.3%, 88.0%, and 95.2%, respectively. An undetectable HCV RNA level by CAM, ART, and CAP/CTM correctly predicted SVR at week 4 in 100%, 100%, and 100% of patients, at weeks 5 to 8 in 91.7%, 100%, and 100% of patients, at weeks 9 to 12 in 55.6%, 75%, and 87.5% of patients, and at weeks 13 to 24 in 0%, 26.7%, and 40% of patients, respectively. Of 16 patients who relapsed after treatment, HCV RNA was detectable in 2 patients at the end of treatment by CAP/CTM but undetectable by ART and CAM. HCV RNA tests using ART and CAP/CTM are considered to be more effective at predicting SVR than CAM, and the PPV for SVR was slightly higher in CAP/CTM than in ART.
Publisher
American Society for Microbiology
Subject
Microbiology (medical)
Reference24 articles.
1. Berg, T., M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, T. Gerlach, P. Buggisch, T. Goeser, J. Rasenack, G. R. Pape, W. E. Schmidt, B. Kallinowski, H. Klinker, U. Spengler, P. Martus, U. Alshuth, and S. Zeuzem. 2006. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology130:1086-1097. 2. Bronowicki, J. P., D. Ouzan, T. Asselah, H. Desmorat, J. P. Zarski, J. Foucher, M. Bourliere, C. Renou, A. Tran, P. Melin, C. Hezode, M. Chevalier, M. Bouvier-Alias, S. Chevaliez, F. Montestruc, I. Lonjon-Domanec, and J. M. Pawlotsky. 2006. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology131:1040-1048. 3. Improved COBAS TaqMan Hepatitis C Virus Test (Version 2.0) for Use with the High Pure System: Enhanced Genotype Inclusivity and Performance Characteristics in a Multisite Study 4. Davis, G. L., J. B. Wong, J. G. McHutchison, M. P. Manns, J. Harvey, and J. Albrecht. 2003. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology38:645-652. 5. Ferenci, P., M. W. Fried, M. L. Shiffman, C. I. Smith, G. Marinos, F. L. Goncales, Jr., D. Haussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, M. Chaneac, and K. R. Reddy. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J. Hepatol.43:425-433.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|